Drug Profile
Coversin - Akari Therapeutics
Alternative Names: Coversin; EV 576; PAS-coversin; rEV 576Latest Information Update: 26 Mar 2018
Price :
*
At a glance
- Originator Evolutec
- Developer Akari Therapeutics; Evolutec
- Class Anti-inflammatories; Recombinant proteins
- Mechanism of Action Complement C5a inhibitors; Leukotriene B4 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Haemolytic uraemic syndrome; Paroxysmal nocturnal haemoglobinuria
- Preclinical Bullous pemphigoid; Conjunctivitis; Myasthenia gravis; Sjogren's syndrome
- No development reported Guillain-Barre syndrome
- Discontinued Asthma; Autoimmune disorders; Inflammation
Most Recent Events
- 21 Mar 2018 Akari Therapeutics receives regulatory approval to initiate phase III CAPSTONE trial in Paroxysmal nocturnal haemoglobinuria in Europe
- 07 Feb 2018 Akari Therapeutics completes the phase II COBALT trial in Paroxysmal nocturnal haemoglobinuria in United Kingdom (SC)
- 06 Feb 2018 Akari Therapeutics plans a phase II trial for Bullous Pemphigoid in first half of 2018